Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Enovix Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Enovix Corporation trades at $5.14 (market cap $1.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 35× Enovix Corporation's market cap. Which is the better fit depends on your goals.
| ALNY | ENVX | |
|---|---|---|
Market Cap | $39.89B | $1.14B |
Sector | Health | Technology |
52-Week High | $491.22 | $15.93 |
52-Week Low | $278.09 | $4.84 |
Enterprise Value | $38.15B | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ENVX trades at $5.20, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue above guidance and an EPS beat of -$0.14 versus -$0.15 expected, but net losses remain substantial at -$156.74M for 2025. Positive developments include the appointment of a former Apple operations leader as COO to scale manufacturing.
The outlook is mixed: strong analyst buy consensus (75%) and a $12.75 price target suggest significant upside, but high cash burn, negative margins, and persistent losses pose substantial execution risks. Investor sentiment hinges on successful production scaling and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
